Skip to main content
SpringerLink
Log in

Ösophaguskarzinom inkl. Karzinome des gastroösophagealen Übergangs

  • Chapter
Evidenzbasierte Viszeralchirurgie maligner Erkrankungen

Part of the book series: Evidenzbasierte Chirurgie ((EC))

  • 1432 Accesses

Zusammenfassung

In der Behandlung von Patienten mit lokalisierten Ösophaguskarzinomen (Tis, T1a und T1b ohne Risikofaktoren, <2 cm) haben sich endoskopischen Verfahren als ausreichende Alternative zur chirurgischen Therapie durchgesetzt. Für Patienten mit resektabler Erkrankung ab T1b stellt die Ösophagektomie mit Interposition eines Schlauchmagens oder in selteneren Fällen eines Kolon- oder Dünndarminterponates das chirurgische Vorgehen der Wahl dar. Für Patienten mit resektablen Tumoren des gastroösophagealen Übergangs werden sowohl die Ösophagektomie als auch die transhiatal erweiterte Gastrektomie durchgeführt. Eine neoadjuvante Vorbehandlung hat sich für fortgeschrittene Stadien ab cT2 durchgesetzt. Eine definitive Radiochemotherapie scheint für Plattenepithelkarzinome vergleichbare onkologische Ergebnisse zu erzielen und wird in den Leitlinien als Alternative berücksichtigt. Bei einem Rezidiv nach definitiver Radiochemotherapie ist eine Salvage-Ösophagektomie möglich.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Ando N, Kato H, Igaki H, et al. (2012) A randomized trial comparing postoperative adjuvant chemotherapy with cisplatin and 5-fluorouracil versus preoperative chemotherapy for localized advanced squamous cell carcinoma of the thoracic esophagus (JCOG9907) Ann Surg Oncol 19:68–74

    Google Scholar 

  • Best LM, Mughal M, Gurusamy KS (2016) Non-surgical versus surgical treatment for oesophageal cancer. Cochrane Database Syst Rev 3:CD011498

    Google Scholar 

  • Bierer SS, van Berge Henegouwen MI, Maas KW, Bonavina L, Rosman C, Garcia JR, Gisbertz SS, Klinkenbijl JH, Hollmann MW, de Lange ES, Bonjer HJ, van der Peet DL, Cuesta MA (2012) Minimally invasive versus open oesophagectomy for patients with oesophageal cancer: a multicentre, open-label, randomised controlled trial. Lancet 379(9829):1887–92

    Google Scholar 

  • Brusselaers N, Mattsson F, Lagergren J (2014) Hospital and surgeon volume in relation to long-term survival after oesophagectomy: systematic review and meta-analysis. Gut 63(9):1393–400

    Google Scholar 

  • Chan DS, Twine CP, Lewis WG (2012) Systematic review and meta-analysis of the influence of HER2 expression and amplification in operable oesophageal cancer. J Gastrointest Surg 16(10):1821–1829

    Google Scholar 

  • Cheng Tan, Xia Qian, Zhifeng Guan, Baixia Yang, Yangyang Ge, Feng Wang, Jing Cai (2016) Potential biomarkers for esophageal cancer. Springerplus 5: 467

    Google Scholar 

  • Choi NC, Gibson MK (2018) Radiation therapy, chemoradiotherapy, neoadjuvant approaches, and postoperative adjuvant therapy for localized cancers of the esophagus. www.uptodate.com

  • Conroy T, Galais MP, Raoul JL, Bouché O, Gourgou-Bourgade S, Douillard JY, Etienne PL, Boige V, Martel-Lafay I, Michel P, Llacer-Moscardo C, François E, Créhange G, Abdelghani MB, Juzyna B, Bedenne L, Adenis A; Fédération Francophone de Cancérologie Digestive and UNICANCER-GI Group (2014) Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. Lancet Oncol 15(3):305–14

    Google Scholar 

  • Crosby T, Hurt CN, Falk S, Gollins S, Staffurth J, Ray R, Bridgewater JA, Geh JI, Cunningham D, Blazeby J, Roy R, Maughan T, Griffiths G, Mukherjee S (2017) Long-term results and recurrence patterns from SCOPE-1: a phase II/III randomised trial of definitive chemoradiotherapy +/- cetuximab in oesophageal cancer. Br J Cancer 116(6):709–716

    Google Scholar 

  • Cunningham D, Allum WH, Stenning SP, et al. (2006) Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11–20

    Google Scholar 

  • Deng HY, Wang WP, Wang YC, Hu WP, Ni PZ, Lin YD, Chen LQ (2017) Neoadjuvant chemoradiotherapy or chemotherapy? A comprehensive systematic review and meta-analysis of the options for neoadjuvant therapy for treating oesophageal cancer. Eur J Cardiothorac Surg 51(3):421–431

    Google Scholar 

  • Depypere LP, Moons J, Mariette C, D’Journo XB, Thomas PA, Hölscher AH, Bollschweiler E, van Berge-Henegouwen MI, Van Lanschot JJB, Lerut TEMR, Nafteux PR (2017) Impact of Extracapsular Lymph Node Involvement After Neoadjuvant Chemoradiation Therapy Followed by Surgery in Carcinoma of the Esophagus: A Multicenter Study. Ann Surg [Epub ahead of print]

    Google Scholar 

  • Franko J, Voynov G, Goldman CD (2016) Esophagectomy Timing After Neoadjuvant Therapy for Distal Esophageal Adenocarcinoma. Ann Thorac Surg 101(3):1123–1130

    Google Scholar 

  • Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, Safran H, Dos Santos LV, Aprile G, Ferry DR, Melichar B, Tehfe M, Topuzov E, Zalcberg JR, Chau I, Campbell W, Sivanandan C, Pikiel J, Koshiji M, Hsu Y, Liepa AM, Gao L, Schwartz JD, Tabernero J; REGARD Trial Investigators (2014) Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet 383(9911):31–39

    Google Scholar 

  • Fuchs HF, Harnsberger CR, Broderick RC, Chang DC, Sandler BJ, Jacobsen GR, Bouvet M, Horgan S (2017) Simple preoperative risk scale accurately predicts perioperative mortality following esophagectomy for malignancy. Dis Esophagus 30(1):1–6

    Google Scholar 

  • Gurusamy KS, Pallari E, Midya S, Mughal M (2016) Laparoscopic versus open transhiatal oesophagectomy for oesophageal cancer. Cochrane Database Syst Rev 3:CD011390

    Google Scholar 

  • Haisley KR, Hart KD, Nabavizadeh N, Bensch KG, Vaccaro GM, Thomas CR Jr, Schipper PH, Hunter JG, Dolan JP (2017) Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer. Dis Esophagus 30(7):1–7

    Google Scholar 

  • Haisley KR, Laird AE, Nabavizadeh N, Gatter KM, Holland JM, Vaccaro GM, Thomas CR Jr, Schipper PH, Hunter JG, Dolan JP (2016) Association of Intervals Between Neoadjuvant Chemoradiation and Surgical Resection With Pathologic Complete Response and Survival in Patients With Esophageal Cancer. JAMA Surg 151(11):e162743

    Google Scholar 

  • Hii MW, Smithers BM, Gotley DC, Thomas JM, Thomson I, Martin I, Barbour AP (2013) Impact of postoperative morbidity on long-term survival after oesophagectomy. Br J Surg 100(1):95–104

    Google Scholar 

  • Hu Y, Li Z, Mi DH, Cao N, Zu SW, Wen ZZ, Yu XL, Qu Y (2017) Chemoradiation combined with regional hyperthermia for advanced oesophageal cancer: a systematic review and meta-analysis. J Clin Pharm Ther 42(2):155–164

    Google Scholar 

  • Karran A, Blake P, Chan D, Reid TD, Davies IL, Kelly M, Roberts SA, Crosby T, Lewis WG (2014) Propensity score analysis of oesophageal cancer treatment with surgery or definitive chemoradiotherapy. Br J Surg 101(5):502–10

    Google Scholar 

  • Kathiravetpillai N, Koëter M, van der Sangen MJ, Creemers GJ, Luyer MD, Rutten HJ, Nieuwenhuijzen GA (2016) Delaying surgery after neoadjuvant chemoradiotherapy does not significantly influence postoperative morbidity or oncological outcome in patients with oesophageal adenocarcinoma. Eur J Surg Oncol 42(8):1183–90

    Google Scholar 

  • Kauppila JH, Xie S, Johar A, Markar SR, Lagergren P (2017) Meta-analysis of health-related quality of life after minimally invasive versus open oesophagectomy for oesophageal cancer. Br J Surg 104(9):1131–1140

    Google Scholar 

  • Kim JY, Correa AM, Vaporciyan AA, Roth JA, Mehran RJ, Walsh GL, Rice DC, Ajani JA, Maru DM, Bhutani MS, Welsh J, Marom EM, Swisher SG, Hofstetter WL (2012) Does the timing of esophagectomy after chemoradiation affect outcome? Ann Thorac Surg 93(1):207–12

    Google Scholar 

  • Klevebro F, Alexandersson von Döbeln G, Wang N, Johnsen G, Jacobsen AB, Friesland S, Hatlevoll I, Glenjen NI, Lind P, Tsai JA, Lundell L, Nilsson M (2016) A randomized clinical trial of neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for cancer of the oesophagus or gastro-oesophageal junction. Ann Oncol 27(4):660–7

    Google Scholar 

  • Koen Talsma A, Shapiro J, Looman CW, van Hagen P, Steyerberg EW, van der Gaast A, van Berge Henegouwen MI, Wijnhoven BP, van Lanschot JJ; CROSS Study Group, Hulshof MC, van Laarhoven HW, Nieuwenhuijzen GA, Hospers GA, Bonenkamp JJ, Cuesta MA, Blaisse RJ, Busch OR, ten Kate FJ, Creemers GJ, Punt CJ, Plukker JT, Verheul HM, van Dekken H, van der Sangen MJ, Rozema T, Biermann K, Beukema JC, Piet AH, van Rij CM, Reinders JG, Tilanus HW (2014) Lymph node retrieval during esophagectomy with and without neoadjuvant chemoradiotherapy: prognostic and therapeutic impact on survival. Ann Surg 260(5):786–92

    Google Scholar 

  • Kurokawa Y, Sasako M, Sano T, Yoshikawa T, Iwasaki Y, Nashimoto A, Ito S, Kurita A, Mizusawa J, Nakamura K; Japan Clinical Oncology Group (JCOG9502) (2015) Ten-year follow-up results of a randomized clinical trial comparing left thoracoabdominal and abdominal transhiatal approaches to total gastrectomy for adenocarcinoma of the oesophagogastric junction or gastric cardia. Br J Surg 102(4):341–8

    Google Scholar 

  • Launoy G, Bossard N, Castro C, Manfredi S; GRELL EUROCARE-5 Working Group (2017) Trends in net survival from esophageal cancer in six European Latin countries: results from the SUDCAN population-based study. Eur J Cancer Prev. 26 Trends in cancer net survival in six European Latin Countries: the SUDCAN study: S24–S31

    Google Scholar 

  • Lee A, Wong AT, Schwartz D, Weiner JP, Osborn VW, Schreiber D (2016) Is There a Benefit to Prolonging the Interval Between Neoadjuvant Chemoradiation and Esophagectomy in Esophageal Cancer? Ann Thorac Surg 102(2):433–8

    Google Scholar 

  • Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): S3-Leitlinie Diagnostik und Therapie der Plattenepithelkarzinome und Adenokarzinome des Ösophagus, Kurzversion 1.0, 2015, AWMF Registernummer: 021/023OL, http://leitlinienprogramm-onkologie.de/Leitlinien.7.0.html (Zugriff am: 15.02.2018)

  • Li Y, Huang HC, Chen LQ, Xu LY, Li EM, Zhang JJ (2017) Predictive biomarkers for response of esophageal cancer to chemo(radio)therapy: A systematic review and meta-analysis. Surg Oncol 26(4):460–472

    Google Scholar 

  • Lin WC, Ding YF, Hsu HL, Chang JH, Yuan KS, Wu ATH, Chow JM, Chang CL, Chen SU, Wu SY (2017) Value and application of trimodality therapy or definitive concurrent chemoradiotherapy in thoracic esophageal squamous cell carcinoma. Cancer 123(20):3904–3915

    Google Scholar 

  • Lordick F, Mariette C, Haustermans K, Obermannová R, Arnold D (2016) Oesophageal Cancer: ESMO Clinical Practice Guidelines. Ann Oncol 27 (suppl 5): v50–v57

    Google Scholar 

  • Lynam-Lennon N, Reynolds JV, Marignol L, Sheils OM, Pidgeon GP, Maher SG (2012) MicroRNA-31 modulates tumour sensitivity to radiation in oesophageal adenocarcinoma. J Mol Med (Berl) 90:1449–1458

    Google Scholar 

  • Maas KW, Cuesta MA, van Berge Henegouwen MI, Roig J, Bonavina L, Rosman C, Gisbertz SS, Biere SS, van der Peet DL, Klinkenbijl JH, Hollmann MW, de Lange ES, Bonjer HJ (2015) Quality of Life and Late Complications After Minimally Invasive Compared to Open Esophagectomy: Results of a Randomized Trial. World J Surg 39(8):1986–93

    Google Scholar 

  • Mariette C, Dahan L, Mornex F, Maillard E, Thomas PA, Meunier B, Boige V, Pezet D, Robb WB, Le Brun-Ly V, Bosset JF, Mabrut JY, Triboulet JP, Bedenne L, Seitz JF (2014) Surgery alone versus chemoradiotherapy followed by surgery for stage I and II esophageal cancer: final analysis of randomized controlled phase III trial FFCD 9901. Clin Oncol 32(23):2416–22

    Google Scholar 

  • Markar SR, Gronnier C, Duhamel A, Mabrut JY, Bail JP, Carrere N, Lefevre JH, Brigand C, Vaillant JC, Adham M, Msika S, Demartines N, Nakadi IE, Meunier B, Collet D, Mariette C; FREGAT (French Eso-Gastric Tumors) working group, FRENCH (Fédération de Recherche EN CHirurgie), and AFC (Association Française de Chirurgie) (2015) The Impact of Severe Anastomotic Leak on Long-term Survival and Cancer Recurrence After Surgical Resection for Esophageal Malignancy. Ann Surg 262(6):972–80

    Google Scholar 

  • Markar SR, Mackenzie H, Lagergren P, Hanna GB, Lagergren J (2016) Surgical Proficiency Gain and Survival After Esophagectomy for Cancer. J Clin Oncol 34(13):1528–36

    Google Scholar 

  • Matsuda S, Tsubosa Y, Niihara M, Sato H, Takebayashi K, Kawamorita K, Mori K, Tsushima T, Yokota T, Ogawa H, Onozawa Y, Yasui H, Takeuchi H, Kitagawa Y (2015) Comparison of transthoracic esophagectomy with definitive chemoradiotherapy as initial treatment for patients with esophageal squamous cell carcinoma who could tolerate transthoracic esophagectomy. Ann Surg Oncol 22(6):1866–73

    Google Scholar 

  • Messager M, Mirabel X, Tresch E et al. (2016), Preoperative chemoradiation with paclitaxel-carboplatin or with fluorouraciloxaliplatin-folinic acid (FOLFOX) for resectable esophageal and junctional cancer: the PROTECT-1402, randomized phase2 trial. BMC Cancer 16: 318

    Google Scholar 

  • Mu J, Gao S, Mao Y, Xue Q, Yuan Z, Li N, Su K, Yang K, Lv F, Qiu B, Liu D, Chen K, Li H, Yan T, Han Y, Du M, Xu R, Wen Z, Wang W, Shi M, Xu Q, Xu S, He J (2015) Open three-stage transthoracic oesophagectomy versus minimally invasive thoraco-laparoscopic oesophagectomy for oesophageal cancer: protocol for a multicentre prospective, open and parallel, randomised controlled trial. BMJ Open 5(11):e008328

    Google Scholar 

  • Nafteux PR, Lerut AM, Moons J, Hölscher AH, Bollschweiler E, van Berge Henegouwen MI, Lagarde SM, van Lanschot JJ, Messager M, Mariette C, D’Journo XB, Thomas PA, De Leyn PR (2015) International Multicenter Study on the Impact of Extracapsular Lymph Node Involvement in Primary Surgery Adenocarcinoma of the Esophagus on Overall Survival and Staging Systems. Ann Surg 262(5):809–15

    Google Scholar 

  • Naik KB, Liu Y, Goodman M, Gillespie TW, Pickens A, Force SD, Steuer CE, Owonikoko TK, Ramalingam SS, Higgins K, Beitler JJ, Shin DM, Willingham FF, El-Rayes B, Landry JC, Fernandez FG, Saba NF (2017) Concurrent chemoradiotherapy with or without surgery for patients with resectable esophageal cancer: An analysis of the National Cancer Data Base. Cancer 123(18):3476–3485

    Google Scholar 

  • Nakamura K, Kato K, Igaki H, et al. (2013) Three-arm phase III trial comparing cisplatin plus 5-FU (CF) versus docetaxel, cisplatin plus 5-FU (DCF) versus radiotherapy with CF (CF-RT) as preoperative therapy for locally advanced esophageal cancer (JCOG1109, NExT study). Jpn J Clin Oncol 43: 752–5

    Google Scholar 

  • Noordman BJ, Shapiro J, Spaander MC, Krishnadath KK, van Laarhoven HW, van Berge Henegouwen MI, Nieuwenhuijzen GA, van Hillegersberg R, Sosef MN, Steyerberg EW, Wijnhoven BP, van Lanschot JJ; SANO study group (2015) Accuracy of Detecting Residual Disease After Cross Neoadjuvant Chemoradiotherapy for Esophageal Cancer (preSANO Trial): Rationale and Protocol. JMIR Res Protoc. 4(2):e79

    Google Scholar 

  • Pasquali S, Yim G, Vohra RS, Mocellin S, Nyanhongo D, Marriott P, Geh JI, Griffiths EA (2017), Survival After Neoadjuvant and Adjuvant Treatments Compared to Surgery Alone for Resectable Esophageal Carcinoma: A Network Meta-analysis. Ann Surg 265(3):481–491

    Google Scholar 

  • Pisarska M, Małczak P, Major P, Wysocki M, Budzyński A, Pędziwiatr M (2017) Enhanced recovery after surgery protocol in oesophageal cancer surgery: Systematic review and meta-analysis. PLoS One. 12(3):e0174382

    Google Scholar 

  • Reynolds JV, Preston SR, O’Neill B, Baeksgaard L, Griffin SM, Mariette C, Cuffe S, Cunningham M, Crosby T, Parker I, Hofland K, Hanna G, Svendsen LB, Donohoe CL, Muldoon C, O’Toole D, Johnson C, Ravi N, Jones G, Corkhill AK, Illsley M, Mellor J, Lee K, Dib M, Marchesin V, Cunnane M, Scott K, Lawner P, Warren S, O’Reilly S, O’Dowd G, Leonard G, Hennessy B, Dermott RM (2017) ICORG 10–14: NEOadjuvant trial in Adenocarcinoma of the Oesophagus and oesophagoGastric junction International Study (Neo-AEGIS). BMC Cancer 17(1):401

    Google Scholar 

  • Robb WB, Dahan L, Mornex F, et al. (2015) Impact of neoadjuvant chemoradiation on lymph node status in esophageal cancer: post hoc analysis of a randomized controlled trial. Ann Surg. 261:902–908

    Google Scholar 

  • Sasako M, Sano T, Yamamoto S, Sairenji M, Arai K, Kinoshita T, Nashimoto A, Hiratsuka M; Japan Clinical Oncology Group (JCOG9502) (2006) Left thoracoabdominal approach versus abdominal-transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol 7(8):644–51

    Google Scholar 

  • Shaikh T, Ruth K, Scott WJ, Burtness BA, Cohen SJ, Konski AA, Cooper HS, Astsaturov I, Meyer JE (2015) Increased time from neoadjuvant chemoradiation to surgery is associated with higher pathologic complete response rates in esophageal cancer. Ann Thorac Surg 99(1):270–6

    Google Scholar 

  • Shapiro J, van Lanschot JJB, Hulshof MCCM, van Hagen P, van Berge Henegouwen MI, Wijnhoven BPL, van Laarhoven HWM, Nieuwenhuijzen GAP, Hospers GAP, Bonenkamp JJ, Cuesta MA, Blaisse RJB, Busch ORC, Ten Kate FJW, Creemers GM, Punt CJA, Plukker JTM, Verheul HMW, Bilgen EJS, van Dekken H, van der Sangen MJC, Rozema T, Biermann K, Beukema JC, Piet AHM, van Rij CM, Reinders JG, Tilanus HW, Steyerberg EW, van der Gaast A; CROSS study group (2015) Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol 16(9):1090–1098

    Google Scholar 

  • Shridhar R, Hoffe SE, Almhanna K, et al. (2013) Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy. Ann Surg Oncol 20:3038–3043

    Google Scholar 

  • Shridhar R, Freilich J, Hoffe SE, Almhanna K, Fulp WJ, Yue B, Karl RC, Meredith K (2014) Single-institution retrospective comparison of preoperative versus definitive chemoradiotherapy for adenocarcinoma of the esophagus. Ann Surg Oncol 21(12):3744–50

    Google Scholar 

  • Stahl M, Walz MK, Stuschke M, et al. (2009) Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 27:851–6

    Google Scholar 

  • Stahl M, Walz MK, Riera-Knorrenschild J, Stuschke M, Sandermann A, Bitzer M, Wilke H, Budach W (2017) Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): Long-term results of a controlled randomised trial. Eur J Cancer 81:183–190

    Google Scholar 

  • Straatman J, van der Wielen N, Cuesta MA, Daams F, Roig Garcia J, Bonavina L, Rosman C, van Berge Henegouwen MI, Gisbertz SS, van der Peet DL (2017) Minimally Invasive Versus Open Esophageal Resection: Three-year Follow-up of the Previously Reported Randomized Controlled Trial: the TIME Trial. Ann Surg 266(2):232–236

    Google Scholar 

  • Sudo K, Xiao, Wadhwa R, Shiozaki H, Elimova E, Taketa T, Blum MA, Lee JH, Bhutani M, Weston B, Ross WA, Komaki R, Rice DC, Swisher SG, Hofstetter WL, Maru DM, Skinner HD, Ajani JA (2014) Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer. J Clin Oncol 32(30):3400–5

    Google Scholar 

  • Tessier W, Gronnier C, Messager M, Hec F, Mirabel X, Robb WB, Piessen G, Mariette C (2014) Does timing of surgical procedure after neoadjuvant chemoradiation affect outcomes in esophageal cancer? Ann Thorac Surg 97(4):1181–9

    Google Scholar 

  • Thumallapally N, Meshref A, Mousa M, Hendawi M, Lan M, Salem AI, Forte F (2017) Survival benefit of neoadjuvant versus adjuvant radiotherapy in lymph node positive esophageal cancer: a population based analysis. J Gastrointest Oncol 8(5): 825–832

    Google Scholar 

  • Union for International Cancer Control (UICC) and the American Cancer Commission (AJCC) (2016) National Comprehensive Cancer Network (NCCN) guidelines for the diagnosis and treatment of esophageal squamous cell carcinoma through the new TNM staging of esophageal carcinoma, https://www.nccn.org, 15.02.2018

  • van Hagen P, et al. (2012) Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 366(22): 2074–84

    Google Scholar 

  • van Putten M, Koëter M, van Laarhoven HWM, Lemmens VEPP, Siersema PD, Hulshof MCCM, Verhoeven RHA, Nieuwenhuijzen GAP (2018) Hospital of Diagnosis Influences the Probability of Receiving Curative Treatment for Esophageal Cancer. Ann Surg 267(2):303–310

    Google Scholar 

  • van Rossum PS, van Hillegersberg R, Lever FM, Lips IM, van Lier AL, Meijer GJ, van Leeuwen MS, van Vulpen M, Ruurda JP (2013) Imaging strategies in the management of oesophageal cancer: what’s the role of MRI? Eur Radiol 23(7):1753–65

    Google Scholar 

  • van Rossum PS, Goense L, Meziani J, Reitsma JB, Siersema PD, Vleggaar FP, van Vulpen M, Meijer GJ, Ruurda JP, van Hillegersberg R (2016) Endoscopic biopsy and EUS for the detection of pathologic complete response after neoadjuvant chemoradiotherapy in esophageal cancer: a systematic review and meta-analysis. Gastrointest Endosc 83(5): 866–79

    Google Scholar 

  • van Workum F, Bouwense SA, Luyer MD, Nieuwenhuijzen GA, van der Peet DL, Daams F, Kouwenhoven EA, van Det MJ, van den Wildenberg FJ, Polat F, Gisbertz SS, Henegouwen MI, Heisterkamp J, Langenhoff BS, Martijnse IS, Grutters JP, Klarenbeek BR, Rovers MM, Rosman C. (2016), Intrathoracic versus Cervical Anastomosis after minimally invasive esophagectomy for esophageal cancer: study protocol of the ICAN randomized controlled trial. Trials 17(1):505

    Google Scholar 

  • Vellayappan BA, Soon YY, Ku GY, Leong CN, Lu JJ, Tey JC (2017) Chemoradiotherapy versus chemoradiotherapy plus surgery for esophageal cancer. Cochrane Database Syst Rev 8:CD010511

    Google Scholar 

  • Visser E, van Rossum PS, Leeftink AG, Siesling S, van Hillegersberg R, Ruurda JP (2017) Impact of diagnosis-to-treatment waiting time on survival in esophageal cancer patients – A population-based study in The Netherlands. Eur J Surg Oncol 43(2): 461–470

    Google Scholar 

  • Visser E, van Rossum PSN, Ruurda JP, van Hillegersberg R (2017) Impact of Lymph Node Yield on Overall Survival in Patients Treated With Neoadjuvant Chemoradiotherapy Followed by Esophagectomy for Cancer: A Population-based Cohort Study in the Netherlands. Ann Surg 266(5):863–869

    Google Scholar 

  • Wang Q, Zhu H, Xiao Z, Zhang W, Liu X, Zhang X, et al. (2013) Expression of epidermal growth factor receptor is an independent prognostic factor for esophageal squamous cell carcinoma. World J Surg Oncol 11:278

    Google Scholar 

  • Wouters MW, Gooiker GA, van Sandick JW, Tollenaar RA (2012) The volume-outcome relation in the surgical treatment of esophageal cancer: a systematic review and meta-analysis. Cancer 1 118 (7): 1754–63

    Google Scholar 

  • Xia BT, Rosato EL, Chojnacki KA, Crawford AG, Weksler B, Berger AC (2013) Major perioperative morbidity does not affect long-term survival in patients undergoing esophagectomy for cancer of the esophagus or gastroesophageal junction. World J Surg 37(2):408–15

    Google Scholar 

  • Xiong WL, Li R, Lei HK, Jiang ZY (2017) Comparison of outcomes between minimally invasive oesophagectomy and open oesophagectomy for oesophageal cancer. ANZ J Surg 87(3):165–170

    Google Scholar 

  • Xu YW, Peng YH, Chen B, Wu ZY, Wu JY, Shen JH, et al. (2014) Autoantibodies as potential biomarkers for the early detection of esophageal squamous cell carcinoma. Am J Gastroenterol 109:36–45

    Google Scholar 

  • Yamashita K, Makino T, Miyata H, Miyazaki Y, Takahashi T, Kurokawa Y, Yamasaki M, Nakajima K, Takiguchi S, Mori M, Doki Y (2016) Postoperative Infectious Complications are Associated with Adverse Oncologic Outcomes in Esophageal Cancer Patients Undergoing Preoperative Chemotherapy. Ann Surg Oncol 23(6):2106–14

    Google Scholar 

  • Yen YC, Chang JH, Lin WC, Chiou JF, Chang YC, Chang CL, Hsu HL, Chow JM, Yuan KS, Wu ATH, Wu SY (2017) Effectiveness of esophagectomy in patients with thoracic esophageal squamous cell carcinoma receiving definitive radiotherapy or concurrent chemoradiotherapy through intensity-modulated radiation therapy techniques. Cancer 123(11):2043–2053

    Google Scholar 

  • Zhang J, Xv Z, Wu X, Li K (2012) Potential diagnostic value of serum p53 antibody for detecting esophageal cancer: a meta-analysis. PLoS ONE 7(12): e52896

    Google Scholar 

  • Zheng Z, Cai J, Yin J, Zhang J, Zhang ZT, Wang KL (2015) Transthoracic versus abdominal-transhiatal resection for treating Siewert type II/III adenocarcinoma of the esophagogastric junction: a meta-analysis. Int J Clin Exp Med 8(10):17167–82

    Google Scholar 

  • Zhou C, Zhang L, Wang H, Ma X, Shi B, Chen W, He J, Wang K, Liu P, Ren Y (2015) Superiority of Minimally Invasive Oesophagectomy in Reducing In-Hospital Mortality of Patients with Resectable Oesophageal Cancer: A Meta-Analysis. PLoS One 10(7):e0132889

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Universität zu Köln, Klinik für Allgemein-, Viszeral- und Tumorchirurgie, Köln, Deutschland

    PD Dr. med. C. Chiapponi & Prof. Dr. med. C. Bruns

  2. Universität zu Köln, Klinik für Allgemein-, Viszeral- und ­Tumorchirurgie, Köln, Deutschland

    Prof. Dr. med. J. Leers

  3. Universität zu Köln, Klinik für Allgemein-, Viszeral- und Tumorchirurgie, Köln, Deutschland

    Prof. Dr. med. W. Schröder

Authors
  1. PD Dr. med. C. Chiapponi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prof. Dr. med. J. Leers
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Prof. Dr. med. W. Schröder
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Prof. Dr. med. C. Bruns
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Universitätsklinikum Würzburg, Würzburg, Deutschland

    Christoph-Thomas Germer

  2. Universitätsklinikum Schleswig-Holstein, Lübeck, Deutschland

    Tobias Keck

  3. ehem. Wissenschaftlich Medizinischer Direktor Kreiskliniken Altötting-Burghausen, Burghausen, Deutschland

    Reinhart T. Grundmann

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature

About this chapter

Cite this chapter

Chiapponi, C., Leers, J., Schröder, W., Bruns, C. (2018). Ösophaguskarzinom inkl. Karzinome des gastroösophagealen Übergangs. In: Germer, CT., Keck, T., Grundmann, R.T. (eds) Evidenzbasierte Viszeralchirurgie maligner Erkrankungen. Evidenzbasierte Chirurgie. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-56533-9_2

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-56533-9_2

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-56532-2

  • Online ISBN: 978-3-662-56533-9

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation